Back | Next |
home / stock / sonn / sonn message board
Subject | By | Source | When |
---|---|---|---|
Nice place!! | limer814 | investorshub | 06/28/2023 2:48:18 PM |
On mini vacation mode, I'm going to Martha's | Carjockey2 | investorshub | 06/28/2023 2:39:45 PM |
Glad to see you're still on this one! | SecondLife | investorshub | 06/28/2023 2:38:28 PM |
Lol Good luck | Carjockey2 | investorshub | 06/28/2023 2:25:03 PM |
No way | govprs | investorshub | 06/28/2023 2:24:38 PM |
https://stockcharts.com/h-sc/ui?s=sonn&p=D&yr=0&mn=6&dy=0&id=p38090673899 htt | surf1944 | investorshub | 06/28/2023 2:16:13 PM |
Looking for 35s | rjack18 | investorshub | 06/28/2023 1:34:19 PM |
Added down here | limer814 | investorshub | 06/28/2023 1:03:43 PM |
Overreaction...Offering was to one tute | Golden Cross | investorshub | 06/28/2023 12:56:47 PM |
Nailed that overbought like I said | starkd748 | investorshub | 06/28/2023 12:49:44 PM |
Expected to close 6-30-23 | Golden Cross | investorshub | 06/28/2023 12:40:32 PM |
$2.25 Million Registered Direct Offering | Golden Cross | investorshub | 06/28/2023 12:36:10 PM |
Dumping like a champ? 30 bid? | Tiger Money | investorshub | 06/28/2023 12:27:06 PM |
Whats going on with the meltdown | govprs | investorshub | 06/28/2023 12:21:24 PM |
very minor 2.25 mill offering, betting tomorrow going | Earlofsandwich | investorshub | 06/28/2023 12:11:37 PM |
EF Hutton Analyst Reiterates Buy Rating for Sonnet | crazy horse 0 | investorshub | 06/28/2023 11:32:01 AM |
PPS predictions in 1 month? | PENNYS ToMILLIONS | investorshub | 06/28/2023 9:06:22 AM |
$SONN SC 13G/A Filing (a) Amount beneficially | crazy horse 0 | investorshub | 06/27/2023 11:44:50 PM |
I like this in the 50s range overbought now | starkd748 | investorshub | 06/27/2023 2:17:03 PM |
Sonnet BioTherapeutics Announces Presentations at the 2023 Cytokine-Based | crazy horse 0 | investorshub | 06/26/2023 11:48:41 PM |
News, Short Squeeze, Breakout and More Instantly...
Sonnet BioTherapeutics Holdings Inc. Company Name:
SONN Stock Symbol:
NASDAQ Market:
Minneapolis, Minnesota--(Newsfile Corp. - May 3, 2024) - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be participating in the EF Hutton Annual Global Conference, which will take place on May 15, 2024 at The P...
PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that preclinical data and clinical trial design from the study of SON-080 (rec...
Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‑080 was reviewed by the study's Data Safety Monitoring Board (DSMB) The adverse event profile and tolerability of SON-080 was consistent with data from previous IL-6 candidates, meeting the Phase...